Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

Deal Expands Existing Cardiovascular Portfolio

 
• By Mandy Jackson
Business people working around M&A on wooden table
Analysts anticipate additional bolt-on deals for Merck • Source: Alamy

More from Deals

More from Business